N. Haddish‐Berhane

On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach

D. Shah, H. Barton, H. Gerber, 2013, Journal of Pharmacokinetics and Pharmacodynamics.

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

N. Girard, R. Govindan, Keunchil Park, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multi-scale stochastic drug release model for polymer-coated targeted drug delivery systems.

O. Campanella, A. Keshavarzian, K. Haghighi, 2006, Journal of controlled release : official journal of the Controlled Release Society.

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

M. Ammirati, J. Treadway, S. Liras, 2011 .

Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin

T. R. Johnson, P. Jasper, J. Tolsma, 2016, The AAPS Journal.

1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC

E. Cho, J. Infante, B. Cho, 2020 .

KRAS: Structure, function, and development of anticancer drugs

D. Parasrampuria, A. Yu, N. Haddish-Berhane, 2020 .

JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).

R. Govindan, Keunchil Park, E. Cho, 2019, Journal of Clinical Oncology.

Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin

D. Shah, N. Haddish-Berhane, A. Betts, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

P76.73 MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab + Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC

S. Shreeve, K. Patel, J. Curtin, 2021 .

P76.74 PAPILLON: Randomized Phase 3 Study of Amivantamab Plus Chemotherapy vs Chemotherapy Alone in EGFR Exon20ins NSCLC

K. Patel, J. Curtin, A. Roshak, 2021 .